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652 The Journal of Thoracic and CardioObjective: We sought to determine the prevalence of defined abnormalities on
surveillance computed tomography after complete resection for non–small cell lung
cancer, as well as the nature and cost of further testing prompted by these abnor-
malities. We also sought to determine whether resectable metachronous lung cancer
can be detected with surveillance scans.
Methods: A retrospective analysis was performed of all patients who presented for
follow-up in 2002 after complete resection for non–small cell lung cancer. Data
collected included demographics, clinicopathologic features of the initial lung
cancer, the number and results of surveillance computed tomographic scans per-
formed in 2002, the attending surgeons’ impressions of the surveillance scans, the
nature of any abnormalities and further diagnostic testing prompted by these
abnormalities, and the nature of any lung cancer detected on surveillance scans, as
well as the treatment rendered. The cost of surveillance scanning and associated
diagnostics was computed by using Medicare fee schedules.
Results: Two hundred thirteen patients met the criteria for inclusion in the study
cohort. One hundred sixty-eight surveillance scans were performed in 140 of these
patients. One hundred five scans were interpreted as abnormal by the radiologist
with regard to pulmonary nodules, adenopathy, or pleural fluid, but the surgeon was
suspicious for recurrent or new primary lung cancer in only 32 of 105 scans. Further
workup revealed recurrent or new primary lung cancer in 16 of 32 patients, with 6
undergoing resection for localized disease. The cost of the surveillance scans and
associated care in the study cohort were 16.6% higher than the cost of care in a
hypothetically identical cohort not subjected to surveillance scanning.
Conclusions: Surveillance computed tomography is frequently abnormal after com-
plete resection for non–small cell lung cancer; however, the majority of these
abnormalities are not clinically suspicious. Resectable metachronous lung cancer is
detected by using surveillance scanning; however, the use of this modality can be
associated with increased cost.
Lung cancer is the leading cause of cancer death in the United Statesfor both men and women.1 Although nearly 174,000 cases of non–small cell lung cancer (NSCLC) are diagnosed annually in thiscountry, only approximately 35,000 undergo surgical resection withcurative intent, primarily because of the limited number of patientswith sufficiently localized disease.1,2 Recurrence after curative re-
section for NSCLC is common, with disease frequently metastasizing to extratho-
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TSracic locations.3 In addition to recurrence of previously
resected NSCLC, a significant number of patients will have
new primary lung cancer distinct from their previously
resected lesion at a rate of approximately 2% per patient per
year of follow-up, a risk that is thought to accumulate over
TABLE 1. Cost of diagnostic testing-procedures
Procedure
Cost
(nearest dollar)
Chest CT* 388
Bone scan* 282
MRI brain* 830
PET* 1761
Thoracentesis
Physician fee 92
Cytology 67
Total 159
Transthoracic FNA
Physician fee-procedure 193
CT guidance 513
Cytology 67
Facility fee 922
Total 1695
Fiberoptic bronchoscopy with biopsy
Physician fee 212
Anesthesia† 280
Pathology‡ 122
Facility fee 865
Total 1479
Cervical mediastinoscopy
Physician fee 524
Anesthesia§ 350
Pathology 122
Facility fee 1263
Total 2259
Thoracoscopy and biopsy
Physician fee 423
Anesthesia¶ 420
Pathology# 206
DRG 28,549
Total 29,598
Total if wedge resection performed 30,238
Thoracotomy–wedge resection
Physician fee–lung resection 1649
Physician fee–lymphadenectomy 310
Anesthesia** 735
Pathology, lung†† 267
Pathology, lymph nodes‡‡ 206
Epidural placement 159
Epidural management§§ 140
DRG 75 28,549
Total 32,015
Total for lobectomy 32,106
Total for segmentectomy 31,968
Total for completion pneumonectomy 32,340time.4,5
The Journal of ThoraciComputed tomography (CT) of the chest has been used
extensively to aid in the diagnosis and staging of NSCLC
for more than 2 decades. Chest CT has also been shown to
be more sensitive than plain chest radiography for detecting
both pulmonary nodules and NSCLC in early stages when
used as a screening tool in populations thought to be at high
risk for development of this disease.6 Finally, although
chest CT is also currently used by many clinicians as a
surveillance tool after surgical resection with curative in-
tent, a paucity of published data exists regarding both its use
in this capacity and the character of abnormalities detect-
ed.7-10 With this as a background, the purpose of this study
is to determine (1) the prevalence of defined abnormalities
detected by means of surveillance CT scans of the chest and
upper abdomen in patients after curative resection for
NSCLC; (2) the quantity, nature, and cost of further diag-
nostic testing prompted by findings on surveillance CT
scans; and (3) the frequency of recurrent or new primary
lung cancer detected by using surveillance CT scans.
Methods
Study Design, Patient Cohort, and Follow-up Regimen
A cross-sectional and retrospective analysis was performed of the
records of all patients with completely resected NSCLC from a
single institution who presented for follow-up in 2002. Approval
for review of office charts and hospital records was obtained from
the institutional review board. To be included in the study cohort,
patients had to have undergone a complete resection (R0) for
NSCLC at any time in the past, regardless of stage or adjuvant-
neoadjuvant treatment, and had to be disease free, with no signs or
symptoms suggestive of recurrent or new primary lung cancer at
the time of their first (or only) follow-up office visit in 2002.
The follow-up regimen, which had been adopted by the authors
TABLE 1. continued
Procedure
Cost
(nearest dollar)
Treatment unresectable stage III and
IV NSCLC
55,185
MRI, Magnetic resonance imaging and gadolinium; PET, positron emission
tomography; FNA, fine-needle aspiration for cytology; DRG, diagnosis related
group.
*Includes performance of study and interpretation.
†One half hour.
‡Level IV.
§Eight-unit base plus one half hour.
Level IV.
¶Eight-unit base plus 1 hour.
#Level V.
**Thirteen-unit base plus 2 hours.
††Level VI.
‡‡Level V.
§§Four days (1 unit/d).
Southwest Oncology Group Trial S9509.12before this analysis, was comprised of an office visit with history
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TSand physical examination every 3 months for the first year after
complete resection, every 6 months for the second year, and yearly
thereafter. Radiographic examinations consisted of a posteroante-
rior and lateral chest radiograph at the time of the office visits at 3,
9, and 18 months after resection. CT generally encompassed the
lung apices through the adrenal glands without intravenous con-
trast and was performed at the time of the office visits at 6 months,
12 months, and yearly thereafter.
Data Collection and Definitions
Data collected included patient demographics, initial tumor histol-
ogy and stage, type and year of resection of the initial tumor, and
the number and date of routine follow-up office visits with the
operating surgeon in 2002. Additional data included the number
and results of surveillance CT scans performed in 2002, the at-
tending surgeons’ impressions of the surveillance scans, the nature
of any abnormalities and further diagnostic testing prompted by
these abnormalities on surveillance scans, the number and nature
of any lung cancer detected on surveillance scans (surveillance
cancers), and the type of treatment rendered for these surveillance
cancers. Also recorded was the number and nature of any lung
cancer that was detected independent of the surveillance CT scans
(interval cancers).
Surveillance CT scans were defined as only those performed in
2002 in patients with no signs or symptoms of lung cancer on
Figure 1. Clinicopathologic features of 213 patients wh
for NSCLC with no signs, symptoms, or both of metach
tumors. B, The pathologic stage of the initial tumors.
responders after induction chemotherapy for stage II
tumors. Adeno, Adenocarcinoma; Squam, squamous cel
specified; BAC, bronchioloalveolar carcinoma; Large, la
type of initial resection performed. Lobe, Lobectomy; P
tectomy; L/CW, lobectomy and chest wall resection; Sl
completion pneumonectomy.history and physical examination at the time of the follow-up
654 The Journal of Thoracic and Cardiovascular Surgery ● Maroffice visit. Any scans performed to evaluate specific complaints or
those in patients with known cancer recurrence were excluded.
Abnormalities were defined as either noncalcified pulmonary nod-
ules, mediastinal or hilar adenopathy (1.5 cm in diameter), or
pleural fluid, as read from the radiologists’ reports. Findings de-
scribed by the radiologist that were consistent with postoperative
change, including thickening, infiltrates, or hemithoracic volume
loss were not considered abnormal.
Although the scan findings were obtained from the radiologists’
reports, as described above, scans were only deemed suspicious for
recurrent or new primary lung cancer if the attending surgeon
altered the previously described follow-up regimen on the basis of
the scan findings (eg, further diagnostic testing was pursued). As
an example, if the radiologist read a scan as showing a pulmonary
nodule but the surgeon did not alter the follow-up regimen, the
scan was classified as not suspicious for recurrent or new primary
lung cancer. In all cases the attending surgeon based his opinion of
the scan (suspicious or not suspicious) on his interpretation of the
combination of both the written radiologists’ reports and his own
impression of the films.
All patients thought to be disease free at the end of 2002
(including those with suspicious surveillance scans in whom re-
current or new primary lung cancer could not be documented)
were confirmed to be disease free in 2003 by means of either office
sented for follow-up in 2002 after complete resection
us lung cancer. A, The year of resection of the initial
2 patients with stage 0 disease represent complete
SCLC. Unk, Unknown. C, The histology of the initial
cinoma; NSC, non–small cell carcinoma, not otherwise
ell carcinoma; AS, adenosquamous carcinoma. D, The
, pneumonectomy; Bilobe, bilobectomy; Seg, segmen-
sleeve lobectomy; Wedge, wedge resection; CPneum,o pre
rono
The
IA N
l car
rge c
neum
obe,visits or telephone contact.
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Costs for all diagnostic testing-procedures performed, as well as
treatments rendered, were obtained from Medicare fee sched-
ules for 2004.11 The cost of facility fees associated with out-
patient procedures (flexible bronchoscopy, mediastinoscopy,
and transthoracic fine-needle aspiration) were obtained from the
hospital billing department and were based on Medicare reim-
bursements obtained by the institution for actual patients un-
dergoing these procedures. The detailed breakdown of costs,
both diagnostic and therapeutic, associated with the perfor-
mance of surveillance CT scans in 2002 is depicted in Table 1.
Treatment of patients who had unresectable stage 3 or 4 disease
was universally assigned a cost of $55,185 on the basis of
published data from an economic analysis of the Southwest
Oncology Group Trial S9509, which determined the cost of the
use of carboplatin and paclitaxel, plus associated costs for the
treatment of advanced (stage 4 and selected stage 3B) NSCLC
adjusted to 2004 dollars.12
To assess the significance of the cost of surveillance CT
scanning, the actual direct and associated cost of performing
these scans in the study cohort was compared with that which
would have been incurred by this same cohort if no surveil-
lance scanning was carried out. The following 3 assumptions
were made to perform this analysis in the absence of long-term
follow-up of the cohort. First, in the group of 16 patients
who presented with recurrent or new primary lung cancer
detected on surveillance CT, it was assumed that only 1 patient,
instead of 6, would have presented with surgically resectable
disease. This assumption is based on existing literature suggest-
ing that only approximately 20% of patients in the United States
who present with lung cancer undergo curative-intent opera-
tions.2
Second, in this group of 6 patients who underwent reresec-
tion for localized metachronous disease, it was assumed that
40% would have been cured of their lung cancer by the second
operation, whereas 60% would have recurred with advanced
disease after the second procedure. This assumption is based on
the results of the 2 largest published series to date on the
curability of early-stage metachronous lung cancer.13,14
Third, it was assumed that the cost of the workup of patients
Figure 2. Distribution of defined abnormalities obtained from ra-
diology reports of 105 abnormal surveillance CT scans.with metachronous lung cancer would be similar, regardless of
The Journal of Thoracistage. Patients with resectable disease usually require radio-
graphic staging studies, as well as an attempt to obtain a tissue
diagnosis in most cases, as do patients with unresectable ad-
vanced disease.
Statistical Analysis
Because this is an observational study, no statistical analysis was
performed.
Results
Study Cohort Characteristics
In 2002, 213 patients presented for at least a single routine
follow-up office visit after previous complete resection for
NSCLC with no signs or symptoms of recurrent or new
primary disease and were included in the study cohort.
There were 101 male and 112 female patients with a mean
age of 67 years. Figure 1 demonstrates the clinicopathologic
features of the initially resected lung cancers, including
tumor stage, histology, year of resection, and type of resec-
tion performed.
Surveillance CT Scans
Of the 213 patients in the study cohort, 140 underwent
surveillance CT scanning. One hundred thirteen patients
had a single scan in 2002, 26 patients had 2 scans, and 1
patient had 3 scans. The 73 patients who did not undergo
surveillance scanning had their resection in the latter half
of 2002, making the 6-month postresection scan fall after
the 2002 calendar year.
One hundred five scans were considered abnormal by
the radiologists’ reports with regard to pulmonary nod-
ules, adenopathy-mediastinal mass, or pleural fluid. Fig-
ure 2 depicts the distribution of these abnormalities
throughout these 105 scans. Despite this high number
of abnormal scans, only 32 (30%) of 105 were thought
TABLE 2. Diagnostic studies instigated by
suspicious surveillance CT scans
Diagnostic study No. performed
CT scan 14
PET 10
CT-guided FNA 7
Thoracoscopy 3
Thoracentesis 3
Cervical mediastinoscopy 2
Fiberoptic bronchoscopy 1
Bone scan 1
Brain MRI 1
Thoracotomy–completion pneumonectomy 1
Thoracotomy–segmentectomy 1
CT, Computed tomography; PET, positron emission tomography; FNA, fine-
needle aspiration; MRI, magnetic resonance imaging.to be suspicious for recurrent or new primary lung
c and Cardiovascular Surgery ● Volume 129, Number 3 655
General Thoracic Surgery Korst et al
G
TScancer by the attending surgeon such that the
follow-up regimen was altered. Follow-up through Janu-
TABLE 3. Resectable metachronous lung cancer detected
by using surveillance CT scans
Patient
no.
Initial
tumor
stage
Disease-
free
interval Resection Pathology
1 IA 13 mo Left lower lobe
wedge
T1 N0
adenocarcinoma
2 IB 30 mo Right upper lobe
wedge
T1 N0
adenocarcinoma
3 IA 3 y Right middle
lobectomy
T2 N0
adenocarcinoma
4 IB 4 y Left upper lobe
segmentectomy
T1 N0
adenocarcinoma
5 IA 5 y Left lower lobe
segmentectomy
T1 N0 BAC
6 IA 8 y Left upper lobe
wedge, left
lower lobe
segmentectomy
T1 N0 BAC, T1 N0
BAC
CT, Computed tomography; BAC, bronchioloalveolar carcinoma.
TABLE 4. Unresectable metachronous lung cancer
detected by using surveillance CT scans
Disease site No. of cases
Mediastinum 3
Pleural fluid–pleura 3
Diffuse lung 2
Chest wall 1
Liver 1
CT, Computed tomography.
TABLE 5. Metachronous lung cancer detected indepen-
dent of surveillance CT scans (interval cases)
No. of
patients
Clinical
presentation
Detection
method Disease site(s)
2 Asymptomatic Physical
examination
Supraclavicular
fossa
2 Constitutional
symptoms
CT scan* Diffuse
metastases
2 Neurologic MRI of brain Brain
1 Constitutional
symptoms
CT scan* Liver
1 Back pain MRI of spine Spine
1 Asymptomatic PET Mediastinum
CT, Computed tomography; MRI, magnetic resonance imaging; PET,
positron emission tomography.
*Not considered a surveillance scan because of the presence of
symptoms.ary 2004 of the patients whose scans were read as ab-
656 The Journal of Thoracic and Cardiovascular Surgery ● Marnormal by the radiologist but not deemed suspicious by
the surgeon (73/105 scans) revealed 5 additional recur-
rences: 1 in the brain, 1 in the liver, and 3 in the pleura.
Rereview of the 2002 CT scan reports for the 4 patients
who had recurrences in the chest and the liver revealed
no abnormalities in the pleura and liver in 2002, implying
that after an extra year of follow-up, the false-negative
rate of the surgeons’ impressions of the 2002 scans was
TABLE 6. Determinants of cost in the surveillance cohort
and corresponding costs in a hypothetical identical cohort
not subjected to surveillance CT scans (see “Methods”
section for details)
Surveillance No surveillance
Surveillance CT scans No cost
Workup of 16 patients with
suspicious scans who had
metachronous lung cancer
Cost identical to
surveillance cohort*
Workup of 16 patients with
suspicious scans who did
not have metachronous
lung cancer
No cost
Surgical resection in 6
patients with resectable
metachronous lung cancer
Cost of surgical resection
in 3 patients with
resectable
metachronous lung
cancer†
No cost Cost of treating the other 3
patients with advanced
disease who would have
undergone resection in
the surveillance cohort†
Cost of treating the 4 patients
who will recur with
unresectable lung cancer
after resection of their
metachronous lung cancer‡
Cost of treating the 1
patient who will recur
with unresectable lung
cancer after resection of
their metachronous lung
cancer‡
Cost of treating 10 patients
with surveillance scans
who had unresectable
metachronous lung cancer
Cost identical to
surveillance cohort
Cost of treating 9 patients
with interval metachronous
unresectable lung cancer
Cost identical to
surveillance cohort
CT, Computed tomography.
*It is assumed that the cost of the workup of a patient with non–small cell
lung cancer would be similar regardless of stage.
†In the absence of surveillance scans, it is assumed that approximately
20% of patients would present with resectable disease, with the remainder
presenting with advanced disease, mimicking the presentation of de novo
lung cancer.2
‡Assuming that 4 of the 6 patients who undergo resection of their resect-
able metachronous lung cancer will recur with advanced disease.150%.
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Prompted by Suspicious Scans
Table 2 shows the variety of further diagnostic studies
pursued in these 32 patients who had scans deemed suspi-
cious by the attending surgeon. In 11 patients the follow-up
regimen was altered simply by either obtaining more fre-
quent CT scans, positron emission tomographic scans, or
both without tissue biopsy, the results of which suggested
no evidence of metachronous lung cancer. Eighteen inva-
sive biopsy procedures were performed, with 12 positive
results (cancer), 5 negative results (no cancer), and 1
aborted procedure because of patient intolerance (attempted
transthoracic fine-needle aspiration). Four patients with ra-
diographic evidence of metastatic disease were treated with-
out histologic confirmation of recurrence. Six patients were
found to have resectable metachronous lung cancer and
underwent resection with curative intent. Table 3 demon-
strates the disease-free interval, operative procedures per-
formed, and pathologic results of these resections.
In addition to the 6 resectable patients, an additional 10
patients were found to have lung cancer that was deemed
unresectable and was detected by means of surveillance
scanning. Table 4 shows the nature of this unresectable
disease. In summary, 16 (50%) of the original 32 patients
with suspicious scans were found to have recurrent or new
primary lung cancer. The remaining 16 patients were re-
garded as disease free after their evaluations and continued
to be followed into 2003.
Interval Lung Cancers
Because all patients in the study cohort were followed
throughout the duration of 2002, the number of interval
(cancers detected independent of surveillance scanning)
lung cancers was also determined. Nine patients had interval
lung cancers in 2002, as defined in this fashion. Table 5
details the clinical presentation and nature of interval lung
cancer in this study cohort.
Cost Analysis
By using the cost breakdown detailed in Table 1, the total
cost of performing surveillance CT scanning and associated
care of patients with recurrent or new primary lung cancer
in the study cohort was $1,658,731 compared with
$1,421,426 for the cost of care in the hypothetically iden-
tical cohort in which no surveillance scanning was per-
formed, resulting in a $237,305 (16.6%) increase in costs as
a result of the surveillance scans. Table 6 lists the compo-
nents of these costs for both of these groups of patients. This
increase corresponds to an additional cost of $1412 for each
scan performed.
Discussion
In a strict sense, all postoperative surveillance CT scans will
be abnormal because of postoperative changes. Therefore it
The Journal of Thoracibecomes necessary to separate those findings thought to be
postsurgical in nature from other abnormalities that might
be more likely to be manifestations of malignancy. The
prevalence of abnormalities on postoperative scans, as well
as the significance of these abnormalities, are virtually un-
known. Given this lack of information, the present obser-
vational study was undertaken to characterize both the na-
ture and frequency of abnormal findings on postoperative
surveillance CT scans of the chest and upper abdomen and
to determine the effect of these abnormalities on the sur-
geon’s decision-making process. In addition, the role of
surveillance CT in detecting resectable metachronous lung
cancer was evaluated, as were the costs associated with
surveillance scanning. The data show that defined abnor-
malities other than postoperative change were common on
surveillance scans; however, these abnormalities were con-
cerning to the attending surgeon only in a minority of cases.
Conversely, when an abnormal scan was thought to be
suspicious by the attending surgeon, recurrent or new pri-
mary lung cancer was only confirmed 50% of the time.
Finally, resectable metachronous lung cancer was detect-
able in a potentially significant minority of patients by using
surveillance CT scans.
Abnormalities Detected on Surveillance CT Scans
Surprisingly few published data exist regarding the preva-
lence of abnormalities on postoperative CT scans, with only
one report commenting on the presence of pulmonary nod-
ules. Lamont and colleagues7 found that 45 (44%) of 102
patients had noncalcified pulmonary nodules on their sur-
veillance scans, which is similar to the 90 (54%) of 168 seen
in the present study. Together, these 2 reports suggest that
the prevalence of pulmonary nodules in patients with pre-
viously resected NSCLC might be relatively high compared
with previously published screened populations with no
history of lung cancer.6 Compared with pulmonary nodules,
the presence of pleural fluid or adenopathy was relatively
uncommon on the surveillance scans. Although pleural fluid
is a common postoperative finding, it usually resolves by the
time the initial surveillance scan is performed at 6 months
after surgical intervention. For this reason, in the present
study pleural fluid was not considered as a postsurgical
change.
In the present study no attempt was made to distinguish
between new CT findings and those noted to be present on
the patients’ scans before their first resections; the purpose
was simply to determine the prevalence of abnormal find-
ings on surveillance scans. Although some of these abnor-
malities might have indeed been present on initial preoper-
ative scans, in many instances these initial scans are not
available to the clinician caring for the patient. Certainly
one reason why some findings on the surveillance scans
might not have been deemed suspicious by the attending
c and Cardiovascular Surgery ● Volume 129, Number 3 657
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for comparison.
As defined in the “Methods” section, scans were classi-
fied as suspicious for recurrent or new primary lung cancer
only when the attending surgeon altered the standard fol-
low-up regimen on the basis of either his interpretation of
the films, the radiologist’s report, or both. By using this
definition, only 30% (32/105) of scans in which the radiol-
ogist listed a defined abnormality were deemed suspicious
by the attending surgeon and subsequently investigated.
This raises the obvious question as to the significance of the
findings on the remaining 73 unsuspicious scans read as
abnormal by the radiologists. Although these patients have
been followed into 2004, a clear weakness of this study is its
cross-sectional nature, with lack of longer-term follow-up.
The only reliable method to answer this important question
is with a prospective and longitudinal study, which the
authors have initiated.
Once scans were deemed suspicious by the attending
surgeon, further testing ranged from more intensive CT
surveillance to diagnostic thoracotomies and lung resec-
tions. An interesting observation was that recurrent or new
primary lung cancer could only be confirmed in 50% (16/
32) of these patients, implying that even the combination of
an abnormal radiologist’s report and a suspicious interpre-
tation by the surgeon only had a specificity of 50% for
malignancy. Once again, further prospective data collection
is needed to determine whether the remaining 16 patients do
indeed have lung cancer in the future and, if so, whether it
is related to the surveillance CT scan abnormalities.
Lung Cancer Detected on Surveillance Scans
In the present study surveillance scanning detected 16 cases
of recurrent or new primary lung cancer in 2002, with 6
(38%) cases being amenable to curative resection. The
distinction between recurrent and second primary lung can-
cer was not defined per se because although criteria have
been published to distinguish new primary from recurrent
disease,15 these criteria are not universally agreed on, par-
ticularly with respect to the disease-free interval. Addition-
ally, the distinction between second primary lung cancer
and a solitary intrapulmonary recurrence (metastasis from
the first tumor) might not be clinically relevant, especially
with the more recent concept of multifocality, which might
be relevant to certain types of NSCLC.16 In contrast to the
cancers detected with surveillance CT, 9 patients in the
study cohort who were being surveyed with CT presented in
2002 with lung cancer independent of surveillance scanning
(interval cancer), and none had resectable disease. Although
2 patients presented with brain metastases, several patients
had disease in the chest, which might represent a failure of
surveillance scanning (Table 5). A weakness of this study is
that the majority of patients who were undergoing CT
658 The Journal of Thoracic and Cardiovascular Surgery ● Marsurveillance in 2002 had their first cancer operated on in
2001 or 2002, limiting the follow-up period. Because many
metachronous lung cancers will present at a later time,
longer follow-up would be ideal for assessing the effect of
surveillance CT scans.
Costs Associated with Surveillance Scanning
In the present study cost figures were based on Medicare
reimbursements for designated procedures. Although this
does not represent the actual realized cost of these proce-
dures that patients and the health care facility incur for these
workups, these figures can be viewed as how much these
patients’ care costs the Medicare system and are useful for
comparative purposes.
This cost analysis consists of 2 components. The first
portion consists of a tabulation of the cost of the surveil-
lance scans, as well as the additional workup and treatment
of abnormalities found on these scans, whereas the second
analysis involves a comparison of this dollar figure to that
from a hypothetical cohort consisting of the very same
patients if they did not undergo surveillance scanning. The
cost data suggest that additional cost might be incurred by
instituting a surveillance CT regimen. However, because the
Medicare fee schedules used in the present study apply to
Manhattan, NY, and these schedules tend to be higher than
those in many other areas of the country, this increase in
cost might be somewhat overestimated. The significance of
this additional cost is difficult to interpret because this study
is not designed to evaluate the cost-effectiveness of surveil-
lance scanning. Longitudinal follow-up data are necessary
to assess the effectiveness of this approach, preferably col-
lected in a prospective fashion. In this regard useful areas of
future investigation might include prospective and longitu-
dinal evaluation of a surveillance CT program, creation of a
decision-analysis model to assess cost-effectiveness, and
finally a randomized prospective trial comparing the use of
surveillance CT with the lack of surveillance. Accrual to
such a randomization, however, might prove to be difficult
given the ease and lack of morbidity associated with sur-
veillance CT scanning.
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Discussion
Dr Keith S. Naunheim (St Louis, Mo). Surveillance testing is
almost universally performed after lung cancer resection but is
highly variable in nature. A few guidelines have been published,
but virtually none of these regimens have been demonstrated
definitively to be beneficial on the basis of hard outcome data.
Several prior publications, including those from my own institu-
tion, have questioned the value of intensive postresection surveil-
lance. Such regimens have not been demonstrated to regularly
identify recurrent cancer at a stage at which further surgical
intervention is likely to be beneficial. Rather, it has been suggested
that the real value of such testing is the detection of second
primary lesions that might allow for subsequent resection and cure.
Into this admixture of supposition and uncertainty, the authors
have introduced a new wrinkle for annual surveillance chest CT.
This article reports on the costs and results of the chest CT scans
performed routinely in asymptomatic patients after lung cancer
resections. It is an observational study and does not purport to
evaluate efficacy of recurrent cancer detection or any survival
effect of testing. Rather, it seeks to identify the incremental costs
of such testing and report the incidence of malignancy, subsequent
resection, or both.
I have some comments and follow-up questions. First, regard-
ing the economic analysis, the authors used the term “cost” when
it would be more correct to use the term “charges.” Charges are
very often used as a surrogate for cost, but as you know, cost is
very difficult, if not impossible, to actually determine. Also, their
computation of costs includes Medicare payments for most phy-
sicians’ fees but fails to include facility costs for some of the
The Journal of Thoracidiagnostic procedures, and this would need to be rectified. These
are minor points, however.
As for the clinical aspects of their article, I also have some
questions. They have suggested that their article deals with both
second primary lung cancers and recurrent disease. However, only
4% of the patients examined were 5 years or more out from their
resection. Accordingly, it is likely that the overwhelming majority
of patients with cancer had recurrent or persistent tumors rather
than second primary lesions. Because of this, I must also question
their assumption that 40% of second resections would be curative.
We have no data to tell us whether these were local or contralateral
recurrences, and all but one were resected through segmentectomy
or wedge resection. I believe the 40% cure figure to be an overly
optimistic one.
None of this, however, greatly detracts from the essential value
of the article. It is a first glimpse at very short-term results of
annual chest CT surveillance after lung cancer resection. Because
of the retrospective nature of this study, the lack of follow-up, and
the absence of a control group, no conclusions are possible regard-
ing the clinical value of this strategy.
In conclusion, I would like to ask the authors several questions.
First, do they routinely recommend resection for all recurrent
cancer presenting as isolated nodules in the postoperative period?
Dr Korst. Thank you, Dr Naunheim, for those constructive
comments.
Do we routinely perform resection for any new pulmonary
nodule that occurs in these patients? The issue, as you brought up,
is clearly whether we think we are dealing with a second primary
lung cancer, and it is a relatively easy decision when the disease-
free interval is at least more than a couple of years, but it gets a
little dicey when you are less than a couple of years our, at which
time I think the issue of resection really needs to be individualized
on a patient-to-patient basis. I can tell you that the shortest disease-
free interval in this study was 13 months, and therefore there was
13 months between the initial cancer, which was a very small stage
I cancer in the right middle lobe, and when this gentleman got
another small lesion in the left lower lobe and had very terrible
lung function, and given that both lesions were very small and
appeared to be clinical stage IA, we went ahead and resected that.
Now was that a new primary lung cancer? Even though the
disease-free interval was short, I think it was. That is obviously
debatable. When you look at the disease-free intervals for those 6
patients, they ranged from 13 months to 8 years. Therefore, obvi-
ously, for the 8-year interval, you are thinking this is a second
primary cancer. But it really has to be individualized when you are
dealing with a patient with a short disease-free interval.
Dr Naunheim. Does the laterality, whether it is an ipsilateral or
a contralateral lesion, make a difference to you?
Dr Korst. The laterality does not, but clearly the location of the
lesion in the chest might make a difference. If you have a lesion
that is close to the hilum in a previously resected patient, you
might worry a little bit more about a recurrence.
Dr Naunheim. And how about the prior tumor stage, the stage
of the first primary lesion?
Dr Korst. All 6 patients that we reresected all had initial
primary lesions that were stage I, and therefore I believe that might
make a difference, and as you correctly pointed out, I cannot
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TSdefinitively say that on the basis of this observational study, but I
think that might come out in any prospective data collection.
Dr Naunheim. How do you decide when to proceed? Your
staging algorithm includes, one would assume, positron emission
tomographic (PET) scanning. Do you do redo mediastinoscopy,
and do you seek a histologic diagnosis on every nodule before
resection?
Dr Korst. No. We did some diagnostic resections, and there-
fore we did not get histology on every patient. We are aggressive
about pursuing metastatic disease, though, and all patients get PET
scans, and anything that lights up on the PET scan we attempt to
biopsy. Therefore we are aggressive to make sure that we are just
operating on persons with a solitary focus in the lung.
Dr Naunheim. Do you intend to continue this relatively inten-
sive surveillance regimen with 6-month, 12-month, and yearly
computed axial tomographic scans? Do you consider that it might
be wasteful and that if other people imitated your institution, we
might be throwing away money, or do you see a prospective trial
anywhere in the future?
Dr Korst. Clearly we need to have prospective data collection.
We are going to continue this for several reasons. The first is that
we now have an institutional review board–approved protocol to
collect data, and we attempt to enroll every patient who comes in
after a complete resection in this protocol. The second reason is
that we did pick up resectable metachronous lung cancer in 6
patients. Therefore we are still not clear on whether this is doing
any good for any patients. Third, at least where we practice, our
belief is that these patients will get CT scans, regardless of whether
we perform them. For that reason, I think, as the operating sur-
geons, that we intimately know the inside of these patients’ chests.
We know what their previous CT scans showed. I think we are
most qualified to know when something is suspicious for either a
recurrence or a new primary lesion. Therefore we would like to do
that. For those reasons, we are going to continue
Dr Naunheim. I would like to congratulate you and your
coauthors on this provocative article. Unfortunately, it raises more
questions than it answers, but still, it is very interesting.
Dr Larry R. Kaiser (Philadelphia, Pa). I am just taking the
prerogative of the chair to ask one question, and Keith mentioned
it just briefly. This issue between costs and charges is a major
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you had cost data, I think it would be even more interesting. As
Keith points out, there is more to cost than the charges that the
patient is billed on a Medicare fee schedule, and in fact, the costs
that are associated with the technical fees are greater by far than
the costs that are associated with the professional fees. Therefore,
if you could get cost data, this would be particularly interesting to
look at in terms of this being a public health issue and in terms of
how best to follow patients who are basically asymptomatic;
obviously the follow-up data are important. Is it possible for you
to get cost data in the future, do you think, as you move forward?
Dr Korst. There are obviously many components of cost, both
direct costs of procedures and so forth and a kind of more subtle
cost, including such costs as time off from work and so forth. I
agree with you. I think that to do a study that aggressively pursues
the issue of cost, that really needs to be the primary focus of the
study and would be worthwhile. There is no question about that.
Dr Altorki. If your hospital is anything like ours, it is almost
impossible to get any information from them about cost, but I
agree with you that in principle that would be ideal.
Dr Stephen D. Cassivi (Rochester, Minn). I have one comment
and one question.
In terms of defining between a separate primary or recurrent
disease, I think you could do that by comparing molecular mark-
ers, such as p53. That is the comment.
My question to you is as follows: What is the outcome of those
patients in whom the surgeon thought the radiologic finding was
not suspicious? I think it will be interesting, in the years to come,
to follow up those patients, those 50% who had lesions that the
surgeon deemed not suspicious.
Dr Korst. There are 73 patients in whom the radiologist read
an abnormality. We did not think it was suspicious. Last week
we went back and called those 73 patients, and in the last year,
which is now a year after this study, there were 4 more recur-
rences: 1 in the brain and 3 in the pleura. We went back and
looked at the chest CT scan reports in 2002 of the ones that
recurred in the pleura, and there were no abnormalities in the
pleura read in 2002. Therefore as the years go on, we will get
more information.
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